PHARNEXT

×

错误信息

  • Notice: Trying to get property 'tid' of non-object 在 eval() (行 35 在 /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Trying to get property 'name' of non-object 在 eval() (行 35 在 /var/www/7/modules/php/php.module(80) : eval()'d code).

Associated tags: Charcot–Marie–Tooth disease, Therapy, CET, Neurodegeneration, Pharmaceutical industry, Regulatory News Service, Security (finance), ISIN, Patient, CMT

Locations: CANADA, EUROPE, UNITED STATES, , ISRAEL, FRANKREICH, PARIS, FRANCE, PA

Pharnext strengthens its ties with Néovacs to secure the next steps in its development

Retrieved on: 
星期日, 一月 22, 2023
Communication, Regulatory News Service, CET, Medtech, Research, CFO, Biotechnology, Patient, Degenerative disease, Confidentiality, Investment, FDA, Therapy, Sciences Po, EMA, Verney-Carron, Marketing, Neurodegeneration, Hugo, Security (finance), Pharmaceutical industry, Health insurance, Management, Euronext

Under the terms of the agreement, Néovacs could become a reference shareholder of Pharnext as of January 1, 2024.

Key Points: 
  • Under the terms of the agreement, Néovacs could become a reference shareholder of Pharnext as of January 1, 2024.
  • This new financing agreement is a partial or total complement to the OCEANE-BSA financing granted by Global Tech Opportunities 13 ("GTO 13").
  • However, Néovacs, through the trust managing its financing contract with Pharnext, has agreed to subscribe to the €1 million tranche scheduled for late December.
  • It was unbelievable that the Company would find itself in difficulty and that is why Néovacs decided to support it.

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Retrieved on: 
星期日, 一月 22, 2023
General counsel, Warner Chilcott, CMC, Regulatory News Service, Master of Pharmacy, CET, United States Department of the Navy, Pharmacovigilance, MD, Johnson & Johnson, Pfizer, Good laboratory practice, Good manufacturing practice, Capsule, Eastern University, Sri Lanka, NDA, BA, Good clinical laboratory practice, Patient, Organization, Regulatory affairs, SLT, Therapy, Charcot–Marie–Tooth disease, Cellectis, Eastern University, Master of Science, Quality assurance, Tablet, Scott, Bachelor of Science, Gan, Doctor of Philosophy, Neurodegeneration, Hugo, Management, Pharmaceutical industry, Medical device, Sanofi, Quality

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Key Points: 
  • Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
    PARIS, France, January 4th, 2023, 08:30 am CET – Pharnext SA (FR001400BV89 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the appointment of Scott Johnson as VP, Head of Quality.
  • Prior to Oyster, Scott served as Director, Quality Assurance at Lupin Pharmaceuticals where he had overall responsibility for quality and compliance.
  • Hugo Brugière, Chairman and Chief Executive Officer of Pharnext, commented: “I look forward to working with Scott and am delighted to welcome him to the Pharnext Senior Leadership Team.

The Board of Directors of Pharnext acknowledges the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company

Retrieved on: 
星期一, 十一月 28, 2022
Committee, Patient, ISIN, Neurodegeneration, CET, Regulatory News Service, Risk, Therapy, Charcot–Marie–Tooth disease, Management, Security (finance), Pharmaceutical industry

The Board of Directors of Pharnext acknowledges the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company

Key Points: 
  • The Board of Directors of Pharnext acknowledges the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The Board of Directors of Pharnext acknowledges the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company
    PARIS, France, November 28th, 2022, 8:30 am CET Pharnext SA (FR001400BV89 - ALPHA) (the Company), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the resignation of Dr. David Horn SOLOMON from his duties as Chief Executive Officer and Director of the Company.
  • At the Board of Directors meeting held on November 27th, 2022, Dr. David Horn SOLOMON presented his resignation, with immediate effect, from his duties as Chief Executive Officer and Director of Pharnext SA.
  • The Board expressed its thanks to Dr. David Horn SOLOMON for his contributions.

Pharnext: completion of the reverse split of its shares on the basis of 1 new share for 5,000 old shares, start of trading of the shares resulting from the reverse split, and capital reductions

Retrieved on: 
星期日, 十一月 27, 2022
Risk, Therapy, Parity, ISIN, Charcot–Marie–Tooth disease, Neurodegeneration, Treasury, Exercise, Security (finance)

These adjustments are applicable from the date of allocation of the new shares resulting from the reverse stock split, i.e.

Key Points: 
  • These adjustments are applicable from the date of allocation of the new shares resulting from the reverse stock split, i.e.
  • The Company also carried out two capital reductions motivated by losses.
  • As a result of this capital reduction, the share capital is reduced from 3,932,043 euros to 39,320.43 euros and is divided into an unchanged number of shares, i.e.
  • Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying treatments.

Hugo Brugière Joins Pharnext Board of Directors

Retrieved on: 
星期五, 十一月 11, 2022
CET, Sciences Po, Risk, ISIN, Board, Regulatory News Service, Board of directors, Charcot–Marie–Tooth disease, Hugo, CEO, Therapy, Neurodegeneration, Trial of the century, Security (finance), Pharmaceutical industry, Management

PARIS, France, on November 8th, 2022 at 8:30am (CET) Pharnext SA (FR0011191287 - ALPHA) (the Company), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces its Board of Directors has appointed Hugo Brugire, Chairman and CEO of Novacs, as a new Director.

Key Points: 
  • PARIS, France, on November 8th, 2022 at 8:30am (CET) Pharnext SA (FR0011191287 - ALPHA) (the Company), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces its Board of Directors has appointed Hugo Brugire, Chairman and CEO of Novacs, as a new Director.
  • This cooptation will be submitted to the approval of the next shareholders meeting of Pharnext.
  • This follows the financing agreement executed between Pharnext and Novacs for an amount of 20.7 million net as announced on October 3rd, 2022.
  • Joshua Schafer, Chairman of Pharnexts Board of Directors, commented: I am delighted to welcome Hugo Brugire as a new member of our Board of Directors as we advance our pivotal Phase III clinical study of PXT3003, the PREMIER trial, which is due to bring top line data in Q4 2023.

Pharnext Reports First Half 2022 Financial Results

Retrieved on: 
星期六, 十月 22, 2022
CET, Therapy, IFRS, GTO, Mission statement, Neurodegeneration, Patient, Company, Board, CEO, Regulatory News Service, Director, Pharmaceutical industry

Following on-schedule completion of patient enrollment, we remain on track to report topline results from our pivotal Phase III PREMIER trial in Q4 2023.

Key Points: 
  • Following on-schedule completion of patient enrollment, we remain on track to report topline results from our pivotal Phase III PREMIER trial in Q4 2023.
  • The first half of 2022 saw Pharnext continue to make significant progress in advancing the development of its lead program, PXT3003, in CMT1A.
  • On April 25, 2022, the Board of Directors appointed Joshua Schafer as Chairman of the Board, following his nomination as interim Chairman on March 28, 2022.
  • The main financial elements are presented in the table below: These are from financial statements established according to IFRS rules and were approved by the Board of Directors at their meeting held on October 14, 2022.

Pharnext announces a reverse stock split and suspension of the right to exercise all the securities giving access to Pharnext's share capital including the conversions of convertible bonds

Retrieved on: 
星期一, 十月 3, 2022
Commercial code, Bulletin, Euronext Paris, Exercise, Sale, Neurodegeneration, CET, Board of directors, Board, Regulatory News Service, Therapy, Security (finance), Renewable energy, Home appliance

This reverse stock split operation aims at reducing Pharnext share price volatility and fostering its stabilization.

Key Points: 
  • This reverse stock split operation aims at reducing Pharnext share price volatility and fostering its stabilization.
  • The reverse stock split is a share exchange transaction with no impact on the amount of share capital: only the par value of the share and, consequently, the number of outstanding shares are modified.
  • The reverse stock split operation will begin on Monday, October 24, 2022, and end on Tuesday, November 22, 2022.The first day of trading for the new post reverse split shares will be Wednesday, November 23, 2022.
  • Practically speaking, each shareholder will be automatically granted one new share per block of 5,000 old shares by their financial intermediary.

Pharnext: Findings on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A From ‘Real-World’ Digital Lifestyle Study, CMT&Me, to be Presented at the American Association of Neuromuscular & Electrodia

Retrieved on: 
星期四, 九月 15, 2022
Therapy, II, ISIN, Prevalence, Convention center, Neurodegeneration, Poster, Life, Muscle atrophy, Medical Affairs Bureau, American Association of Neuromuscular & Electrodiagnostic Medicine, American Association, Electrodiagnostic medicine, AANEM, Charcot–Marie–Tooth disease, Patient, Wheelchair, PMP22, III, Schwann cell, Pain, Quality of life, CMT, Walking, Running, Degenerative disease, CET, Regulatory News Service, Conference, Association, Occupational therapy, Gaylord Opryland Resort & Convention Center, Pharmaceutical industry, Security (finance), Medical device, Television

Pharnext: Findings on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A From Real-World Digital Lifestyle Study, CMT&Me, to be Presented at the American Association of Neuromuscular & Electrodia

Key Points: 
  • Pharnext: Findings on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A From Real-World Digital Lifestyle Study, CMT&Me, to be Presented at the American Association of Neuromuscular & Electrodia
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The conference is taking place from September 21-24, 2022, in-person and with an option to participate virtually, at Gaylord Opryland Resort & Conference Center in Nashville, Tennessee.
  • Charcot-Marie-Tooth (CMT) disease encompasses a heterogeneous group of inherited, severe, debilitating, progressive and chronic peripheral neuropathies.
  • The genetic mutation responsible for CMT1A is a duplication of the PMP22 gene coding for a peripheral myelin protein.

Pharnext: Findings From ‘Real-World’ Digital Lifestyle Study, CMT&Me, on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A Published in the Journal of Clinical Neuromuscular Disease

Retrieved on: 
星期三, 九月 14, 2022
Journal, Hackensack Meridian School of Medicine, Patient, PMP22, CMT, Occupational therapy, Anxiety, Disease, Hackensack University Medical Center, Extremities, ISIN, Prevalence, Life, Muscle atrophy, Charcot–Marie–Tooth disease, Weakness, Pain, Doctor of Philosophy, Depression, MD, Population, Wheelchair, Department of Neurology, Xuanwu hospital, Walking, Schwann cell, Running, CET, Fatigue, HIV disease progression rates, Therapy, Department, Neurodegeneration, Neurology, Foot, Quality of life, Diagnosis, Caregiver, Regulatory News Service, Awareness, Education, Pharmaceutical industry, Security (finance), Medical device

Pharnext: Findings From Real-World Digital Lifestyle Study, CMT&Me, on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A Published in the Journal of Clinical Neuromuscular Disease

Key Points: 
  • Pharnext: Findings From Real-World Digital Lifestyle Study, CMT&Me, on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A Published in the Journal of Clinical Neuromuscular Disease
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The findings on patients with the 1A subtype of CMT (CMT1A) showed that patient-reported symptoms burden is high, with study participants registering difficulties using limbs, fatigue, pain, and impaired quality of life.
  • Burden severity appears to differ across the population, possibly driven by differences in rehabilitative and prescription-based interventions, and country-specific health care variability.
  • The article, titled, Patient-Reported Symptom Burden of CharcotMarieTooth Disease Type 1A: Findings From an Observational Digital Lifestyle Study can be accessed online here .

Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial

Retrieved on: 
星期一, 九月 12, 2022
Safety, Therapy, ISIN, Sorbitol, FDA, ClinicalTrials.gov, Prevalence, Neurodegeneration, Life, Baclofen, Muscle, Muscle atrophy, Treatment, Patient, Wheelchair, Risk, Phase II, PMP22, III, Schwann cell, Walking, Running, CMT, CET, Charcot–Marie–Tooth disease, Regulatory News Service, Naltrexone, HD, Occupational therapy, Marketing, EMA, Disease, Pharmaceutical industry, Security (finance)

Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial

Key Points: 
  • Pharnext Announces First Patient Enrolled in Open Label Extension of the Pivotal Phase III Study of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A, the PREMIER Trial
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The dose of PXT3003 tested in the PREMIER trial corresponds to the HD tested in the prior Phase III clinical study, the PLEO-CMT trial, and the ongoing open-label extension Phase III study, the PLEOCMT-FU trial.
  • The dose of PXT3003 tested in the PREMIER trial corresponds to the high dose (HD) tested in the prior Phase III trial (PLEO-CMT).
  • An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing.